Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Di | Outlook Therapeutics, Inc.: Outlook Therapeutics® to Present at the Virtual Investor Pitch Conference | 2 | GlobeNewswire (USA) | ||
28.05. | Outlook Therapeutics, Inc.: Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA (bevacizumab gamma) for the Treatment of Wet AMD | 15 | GlobeNewswire (USA) | ||
15.05. | Outlook Therapeutics, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
15.05. | Outlook Therapeutics, Inc.: Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate Update | 224 | GlobeNewswire (Europe) | Positive opinion received from Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for ONS-5010/LYTENAVA (bevacizumab gamma)United Kingdom (UK) Marketing Authorization... ► Artikel lesen | |
13.05. | Outlook Therapeutics, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
13.05. | Outlook Therapeutics, Inc.: Outlook Therapeutics Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD | 135 | GlobeNewswire (Europe) | UK submission for national MAA review follows recently received positive opinion from Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) concerning the authorization... ► Artikel lesen | |
09.05. | Outlook Therapeutics, Inc.: Outlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and Webcast | 10 | GlobeNewswire (USA) | ||
02.05. | Outlook Therapeutics, Inc.: Outlook Therapeutics® to Present at the Retina World Congress 2024 | 8 | GlobeNewswire (USA) | ||
01.05. | Outlook Therapeutics, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
29.04. | Outlook Therapeutics, Inc.: Outlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase | 12 | GlobeNewswire (USA) | ||
15.04. | Outlook Therapeutics, Inc.: Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million | 10 | GlobeNewswire (USA) | ||
12.04. | Outlook Therapeutics, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
02.04. | Outlook Therapeutics, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
28.03. | Outlook Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 8 | SEC Filings | ||
26.03. | Outlook Therapeutics, Inc. - 8-K, Current Report | 9 | SEC Filings | ||
22.03. | Outlook Therapeutics, Inc.: Outlook Therapeutics Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD | 161 | GlobeNewswire (Europe) | Positive opinion serves as a basis for final decision for potential authorization from the European Commission (EC), expected within 67 days ISELIN, N.J., March 22, 2024 (GLOBE NEWSWIRE) -- Outlook... ► Artikel lesen | |
18.03. | Outlook Therapeutics, Inc. - 8-K, Current Report | 6 | SEC Filings | ||
18.03. | Outlook Therapeutics, Inc.: Outlook Therapeutics® Announces Closing of Private Placement of up to $159 Million | 5 | GlobeNewswire (USA) | ||
12.03. | Outlook Therapeutics, Inc.: Outlook Therapeutics Announces Effective Date for 1-for-20 Reverse Stock Split | 345 | GlobeNewswire (Europe) | ISELIN, N.J., March 12, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the "Company"), a biopharmaceutical company working to achieve FDA approval for the first ophthalmic formulation... ► Artikel lesen | |
07.03. | Outlook Therapeutics, Inc. - 8-K, Current Report | 4 | SEC Filings |
Suchbegriffe der letzen 24 h | Anzahl |
---|---|
NVIDIA | 495 |
SNOWFLAKE | 309 |
TUI | 305 |
GAMESTOP | 282 |
RHEINMETALL | 261 |
EVOTEC | 226 |
NEL | 192 |
DEUTSCHE LUFTHANSA | 183 |
BAYER | 169 |
BYD | 160 |
TESLA | 143 |
VOLKSWAGEN | 119 |
BASF | 116 |
APPLE | 109 |
THYSSENKRUPP | 99 |
PORSCHE SE | 98 |
DEUTSCHE TELEKOM | 94 |
MERCEDES-BENZ | 90 |
ALLIANZ | 87 |
DEUTSCHE BANK | 85 |
SUPER MICRO COMPUTER | 79 |
COMMERZBANK | 78 |
AMAZON | 76 |
THYSSENKRUPP NUCERA | 73 |
RWE | 72 |